A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.

Trial Details

NCT ID
NCT07087158
Phase
PHASE2
Sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • IBR854
  • Pazopanib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female, age ≥ 18 years old
  • Advanced clear cell renal cell carcinoma confirmed by histology or cytology and not amenable to curative surgery.
  • Has not received any previous systemic anti-tumor treatment for advanced renal cell carcinoma.
  • Expected survival period is at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →